CIENCIASMEDICASNEWS

miércoles, 12 de agosto de 2026

1 year of The Lancet Primary Care The Lancet Primary Care +... +

1 year of The Lancet Primary Care The Lancet Primary Care https://www.thelancet.com/journals/lanprc/issue/vol2no7/PIIS3050-5143(26)X2007-6 Weight status and pathways to eating disorder referral from primary care in England and Northern Ireland: a cross-sectional analysis of routine care data Chloe Gao, BHSca,b,∗ Send email to gaoc1234@student.ubc.ca ∙ Jessica Wilkins, MEda,∗ ∙ Alex Dregan, PhDc ∙ Karina L Allen, PhDa,d ∙ Jamie Scuffell, MBChBe ∙ Prof Ulrike Schmidt, MD PhD https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00075-0/fulltext?dgcid=raven_jbs_etoc_feature_lanprc

The mechanism debate in psilocybin therapy for depression eBioMedicine +... + +

The mechanism debate in psilocybin therapy for depression eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol130nonull/PIIS2352-3964(26)X2006-0 Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men Hatim Kernissa,b,c Send email to Kerniss@med.uni-frankfurt.de ∙ Philip Curmanb,d,e,f ∙ Henning Olbrichg ∙ Khalaf Kridinb,h,i ∙ Rohin Francisj ∙ David M. Leistnera,c ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00256-2/fulltext?dgcid=raven_jbs_etoc_feature_ebiom Microcephaly-like phenotype triggered by novel reassortant and prototypic Oropouche virus strains in brain organoids Gabrielle Bruma,k ∙ Vivian Grizentea,k ∙ Fábio Luís Lima Monteirob,k ∙ Beatriz Luzia de Mello Lima Guimarãesa ∙ Livia Goto-Silvaa ∙ João Marcos de Azevedo Deloua ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00292-6/fulltext?dgcid=raven_jbs_etoc_feature_ebiom

Calla Lily joins $50M program targeting antibiotic resistance A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/calla-lily-joins-50m-program-targeting-antibiotic-resistance-17427 Antimicrobial resistance (AMR) is increasingly recognized as a consequence not only of antibiotic-resistant bacteria, but also of the collateral effects of antibiotic treatment. Antibiotic administration can profoundly alter the composition and diversity of the gut microbiota, disrupt homeostasis, and create selective pressure that promotes the proliferation of antibiotic-resistant bacteria. According to Wellcome Leap, 85–90 percent of bacterial infections are localized, while nearly all antibiotics are delivered systemically.

Immunotherapy drug successfully reduced antibodies to allow kidney transplantation The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/immunotherapy-drug-successfully-reduced-antibodies-to-allow-kidney-transplantation-17424 A 37-year-old man who once had no hope of receiving a matched donor kidney is now living dialysis-free with a new kidney that has excellent function. After spending 12 years on an organ waiting list, the joyful outcome came thanks to a new drug recently approved from Johnson & Johnson to treat multiple myeloma, called teclistamab. The drug is a bispecific T cell engager antibody that works by activating T cells and binding to B-cell maturation antigen (BCMA) on the target cells to tag them for destruction.

Why degrading BTK is a different proposition than inhibiting it The Nurix and Roche partnership on bexobrutideg is the latest sign that targeted protein degradation is moving well beyond oncology. Written byAndrea Corona

https://www.drugdiscoverynews.com/why-degrading-btk-is-a-different-proposition-than-inhibiting-it-17428?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8sM96BRaPG-nlKrZw1tDw5iXBSRYqTuEJp8BJf1XRrT-MuBQbJixW6KiVi2cOizgI166vfDFRb87cXEJR_Q7Ayb1nLnw&_hsmi=432711347&utm_content=432711347&utm_source=hs_email Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of B-cell malignancies over the past decade. Ibrutinib's approval in 2013 validated BTK as a drug target, and a succession of second-generation inhibitors — acalabrutinib, zanubrutinib, pirtobrutinib — have extended that validation with improved selectivity and tolerability. More recently, BTK inhibition has moved into autoimmune disease: The FDA approved remibrutinib and rilzabrutinib in 2025 for chronic spontaneous urticaria (CSU) and immune thrombocytopenia, respectively, and multiple Phase 2 and Phase 3 trials in multiple sclerosis (MS) are underway.

Elevated use of cannabis, nicotine among U.S. adults continues into 2025

Elevated use of cannabis, nicotine among U.S. adults continues into 2025 National survey suggests that use of alcohol, cigarettes, and other substances remains low. In 2025, adults in the United States reported using cannabis at or near record-high levels, continuing a long-term trend of increasing use. Nicotine vaping also remained high among young adults. These findings are based on the latest report from the Monitoring the Future (MTF) Longitudinal Panel Study, an annual examination of self-reported drug use in the U.S. among adults ages 19 to 65 supported by the National Institutes of Health (NIH) since its inception in 1976. https://www.nih.gov/news-events/news-releases/elevated-use-cannabis-nicotine-among-us-adults-continues-into-2025